Skip to main content
. Author manuscript; available in PMC: 2022 Oct 31.
Published in final edited form as: Nat Rev Clin Oncol. 2022 May 9;19(8):499–514. doi: 10.1038/s41571-022-00639-9

Figure 1. Timeline of genomic discoveries and drug development in EGFR-mutant and ALK-rearranged NSCLCs.

Figure 1.

Key events, in a. ∣ EGFR-mutant non-small-cell lung cancers (NSCLC) and b. ∣ ALK-rearranged NSCLC, including the discovery of the oncogenic drivers and gene alterations (orange), FDA approvals of tyrosine-kinase inhibitors for unselected patients (grey), approvals of therapies for biomarker-selected populations in the advanced-stage disease setting (blue), approvals for biomarker-selected populations in the adjuvant setting (green), and important ongoing trials (purple).